Thursday, June 11, 2026

Patent directory Β· USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code β€” or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 103 of 1,261
  1. US 12053481

    Compositions and methods for deep dermal drug delivery

    ARCUTIS BIOTHERAPEUTICS, INC. Β· Granted Aug 6, 2024 Β· Expires Aug 1, 2044

    granted
  2. US 12053519

    HIV-1 Env fusion peptide nanoparticle carrier conjugates and their use

    The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Aug 6, 2024 Β· Expires Aug 1, 2044

    granted
  3. US 12054532

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. Β· Granted Aug 6, 2024 Β· Expires Aug 1, 2044

    granted
  4. US 12053534

    Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging

    REGENERON PHARMACEUTICALS, INC. Β· Granted Aug 6, 2024 Β· Expires Aug 1, 2044

    granted
  5. IT 202300001434

    PRODOTTO DI FERMENTAZIONE PER USO NEL TRATTAMENTO DI PATOLOGIE ASSOCIATE ALLA SINDROME METABOLICA E STEATOSI EPATICA.

    ALFASIGMA SPA [IT] Β· Granted Aug 1, 2024 Β· Expires Jul 27, 2044

    granted
  6. US 12049464

    Compounds for targeted degradation of BRD9

    C4 THERAPEUTICS, INC. Β· Granted Jul 30, 2024 Β· Expires Jul 25, 2044

    granted
  7. US 12048687

    Methods of recruiting SDF-producing macrophages

    MedRegen, LLC Β· Granted Jul 30, 2024 Β· Expires Jul 25, 2044

    granted
  8. US 12048747

    Substituted piperidine Degronimers for Target Protein degradation

    C4 THERAPEUTICS, INC. Β· Granted Jul 30, 2024 Β· Expires Jul 25, 2044

    granted
  9. US 12048748

    Spirocyclic degronimers for target protein degradation

    C4 THERAPEUTICS, INC. Β· Granted Jul 30, 2024 Β· Expires Jul 25, 2044

    granted
  10. US 12049505

    Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof

    CytomX Therapeutics, Inc. Β· Granted Jul 30, 2024 Β· Expires Jul 25, 2044

    granted
  11. US 12049510

    Chimeric antigen receptor

    AUTOLUS LIMITED Β· Granted Jul 30, 2024 Β· Expires Jul 25, 2044

    granted
  12. US 12049457

    Highly purified pharmaceutical grade tasimelteon

    VANDA PHARMACEUTICALS INC. Β· Granted Jul 30, 2024 Β· Expires Jul 25, 2044

    granted
  13. US 12049489

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. Β· Granted Jul 30, 2024 Β· Expires Jul 25, 2044

    granted
  14. US 12048691

    High dosage tebipenem pivoxil tablet formulation

    SPERO THERAPEUTICS, INC. Β· Granted Jul 30, 2024 Β· Expires Jul 25, 2044

    granted
  15. US 12048692

    Methods for treating chronic obstructive pulmonary disease

    Theravance Biopharma R&D IP, LLC Β· Granted Jul 30, 2024 Β· Expires Jul 25, 2044

    granted
  16. US 12049644

    Platform for generating safe cell therapeutics

    The Regents of the University of California Β· Granted Jul 30, 2024 Β· Expires Jul 25, 2044

    granted
  17. US 12049479

    Foot and mouth disease virus (FMDV) consensus proteins, coding sequences therefor and vaccines made therefrom

    Inovio Pharmaceuticals, Inc. Β· Granted Jul 30, 2024 Β· Expires Jul 25, 2044

    granted
  18. US 12049487

    Universal chimeric antigen receptor T-cell preparation technique

    GRACELL BIOTECHNOLOGIES (SHANGHAI) CO., LTD. Β· Granted Jul 30, 2024 Β· Expires Jul 25, 2044

    granted
  19. US 12049471

    Cyano cyclobutyl compounds for Cbl-b inhibition and uses thereof

    NURIX THERAPEUTICS, INC. Β· Granted Jul 30, 2024 Β· Expires Jul 25, 2044

    granted
  20. US 12048317

    Astaxanthin-containing condiment and a preparation method therefor

    South China University of Technology Β· Granted Jul 30, 2024 Β· Expires Jul 25, 2044

    granted
  21. US 12049520

    Bicyclic peptide ligands specific for CD137

    BicycleTx Limited Β· Granted Jul 30, 2024 Β· Expires Jul 25, 2044

    granted
  22. US 12049642

    Corneal endothelial cells with increased cell density and compositions thereof

    Astellas Institute for Regenerative Medicine Β· Granted Jul 30, 2024 Β· Expires Jul 25, 2044

    granted
  23. US 12048699

    Cancer treatment methods based on TP53 mutation status and hypermutation

    Takeda Pharmaceutical Company Limited Β· Granted Jul 30, 2024 Β· Expires Jul 25, 2044

    granted
  24. US 12049630

    Factor XII (F12) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. Β· Granted Jul 30, 2024 Β· Expires Jul 25, 2044

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search β€” best for looking up a specific filing or applicant portfolio slice.